<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00270296</url>
  </required_header>
  <id_info>
    <org_study_id>BHP 016</org_study_id>
    <secondary_id>U01AI064002</secondary_id>
    <nct_id>NCT00270296</nct_id>
  </id_info>
  <brief_title>Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV</brief_title>
  <official_title>Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child
      transmission (MTCT) of HIV in developed countries. However, little is known of the
      effectiveness of such regimens in developing countries, such as Botswana. This study will
      determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and
      zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV)
      is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected
      pregnant women in Botswana.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While perinatal HIV infection has become rare in developed countries through the use of
      highly active antiretroviral therapy (HAART), it remains a serious problem in developing
      countries. Botswana has a population of approximately 1.7 million; the prevalence of HIV in
      Botswana is about 37.4%. In the developed world, HAART has revolutionized the prevention of
      MTCT among nonbreastfed infants. This trial will compare the effectiveness of a protease
      inhibitor (PI)-based regimen versus a triple nucleoside reverse transcriptase inhibitor
      (NRTI)-based regimen in preventing MTCT of HIV.

      This study will last up to 24 months for mothers and their children. Participants will be
      stratified based on their CD4 count at screening. Women with CD4 counts of 200 cells/mm3 or
      more will be in one of two treatment groups and will be randomly assigned to receive either
      TZV twice daily or LPV/RTV and 3TC/ZDV twice daily. Once in labor, treatment group
      participants will continue to take their assigned HAART regimen and will also be given
      additional ZDV. Women with CD4 counts less than 200 cells/mm3 will receive nevirapine (NVP)
      once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will
      be in the observational group.

      Shortly after birth, infants will receive single-dose NVP. A 1-month supply of ZDV will be
      provided to the mother to administer daily to her child. Mothers will stop HAART at 6 months
      postpartum or when they stop breastfeeding, whichever occurs earlier. A clinical evaluation,
      blood collection, and HIV prevention counseling will occur at all maternal visits. An
      obstetrical exam and physical exam will occur at selected visits. Women will provide at least
      four samples of breast milk during the first 5 months postpartum. For infants, a clinical
      evaluation will occur at every visit, and a physical exam and blood collection will occur at
      selected visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Virologic Suppression</measure>
    <time_frame>Throughout study, including breastfeeding, assessed up to 24 months</time_frame>
    <description>Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV+ Infants</measure>
    <time_frame>Throughout study, including breastfeeding, assessed up to 24 months</time_frame>
    <description>Number of infants with HIV-positive status</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">730</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Trizivir (TZV) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kaletra Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevirapine (NVP) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trizivir</intervention_name>
    <description>300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
    <arm_group_label>Trizivir (TZV) Arm</arm_group_label>
    <other_name>TZV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
    <description>150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
    <arm_group_label>Kaletra Arm</arm_group_label>
    <other_name>3TC/ZDV</other_name>
    <other_name>Combivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
    <arm_group_label>Kaletra Arm</arm_group_label>
    <other_name>LPV/RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
    <arm_group_label>Nevirapine (NVP) Arm</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Mothers:

          -  HIV-infected

          -  At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy
             (observational group) but not beyond the 34th week of pregnancy

          -  Able to complete study visits until at least 6 months postpartum

          -  Citizen of Botswana

        Exclusion Criteria for Mothers:

          -  Taken ARVs for more than 1 week, other than ZDV, during current or prior pregnancy.
             Women who have received single-dose NVP in a prior pregnancy are not excluded.

          -  Certain abnormal laboratory values

          -  Plan to formula feed

          -  Known fetal abnormalities that suggest the fetus will not survive to 6 months of
             gestational age

          -  Known allergy or medical contraindication to any of the study drugs

          -  Require certain medications

          -  Previous participation in the &quot;Prevention of Milk-Borne Transmission of HIV-1C in
             Botswana&quot; (Mashi) study

          -  Currently incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Shapiro, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Botswana-Harvard School of Public Health Partnership for Research and Education</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Moffat, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Botswana-Harvard School of Public Health Partnership for Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Marina Hosp., BHP Study Clinic, Gaborone Shapiro CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athlone Hosp., BHP Study Clinic, Lobatse Shapiro CRS</name>
      <address>
        <city>Lobatse</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Reteif Hosp., BHP Study Clinic, Mochudi Shapiro CRS</name>
      <address>
        <city>Mochudi</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottish Livingstone Hosp., BHP Study Clinic, Molepolole Shapiro CRS</name>
      <address>
        <city>Molepolole</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <link>
    <url>https://aidsinfo.nih.gov/drugs/325/abacavir---lamivudine---zidovudine/0/patient</url>
    <description>Click here for more information about abacavir/lamivudine/zidovudine</description>
  </link>
  <link>
    <url>https://aidsinfo.nih.gov/drugs/316/lopinavir---ritonavir/0/patient</url>
    <description>Click here for more information about lopinavir/ritonavir</description>
  </link>
  <link>
    <url>https://aidsinfo.nih.gov/drugs/285/combivir/164/professional</url>
    <description>Click here for more information about lamivudine/zidovudine</description>
  </link>
  <link>
    <url>https://aidsinfo.nih.gov/drugs/116/nevirapine/0/patient</url>
    <description>Click here for more information about nevirapine</description>
  </link>
  <link>
    <url>https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/24/70/hiv-medicines-during-pregnancy-and-childbirth</url>
    <description>Click here for more information about HIV and pregnancy</description>
  </link>
  <reference>
    <citation>Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.</citation>
    <PMID>11981365</PMID>
  </reference>
  <reference>
    <citation>Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL; International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10;288(2):189-98.</citation>
    <PMID>12095383</PMID>
  </reference>
  <reference>
    <citation>Jones BM, Chiu SS, Wong WH, Lim WW, Lau YL. Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy. MedGenMed. 2005 May 3;7(2):71.</citation>
    <PMID>16369449</PMID>
  </reference>
  <reference>
    <citation>Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL; South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003 Mar 1;187(5):725-35. Epub 2003 Feb 24.</citation>
    <PMID>12599045</PMID>
  </reference>
  <reference>
    <citation>Richardson BA, John-Stewart GC, Hughes JP, Nduati R, Mbori-Ngacha D, Overbaugh J, Kreiss JK. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis. 2003 Mar 1;187(5):736-40. Epub 2003 Feb 12.</citation>
    <PMID>12599046</PMID>
  </reference>
  <reference>
    <citation>Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, Kreiss JK, Overbaugh J. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis. 2003 Mar 1;187(5):741-7. Epub 2003 Feb 18.</citation>
    <PMID>12599047</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2005</study_first_posted>
  <results_first_submitted>March 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <disposition_first_submitted>March 26, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2010</disposition_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>MTCT</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TZV Arm</title>
          <description>Participants in Arm 1A will have CD4 counts of 200 cells/mm3 or more and will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Trizivir: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
        </group>
        <group group_id="P2">
          <title>Kaletra Arm</title>
          <description>Participants in Arm 1B will have CD4 counts of 200 cells/mm3 or more and will receive LPV/RTV and 3TC/ZDV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Lamivudine/Zidovudine: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Lopinavir/Ritonavir: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
        </group>
        <group group_id="P3">
          <title>NVP Arm</title>
          <description>Participants in Arm 2 will have CD4 counts less than 200 cells/mm3 and will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
Nevirapine: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="275"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TZV Arm</title>
          <description>Participants in Arm 1A will have CD4 counts of 200 cells/mm3 or more and will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Trizivir: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
        </group>
        <group group_id="B2">
          <title>Kaletra Arm</title>
          <description>Participants in Arm 1B will have CD4 counts of 200 cells/mm3 or more and will receive LPV/RTV and 3TC/ZDV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Lamivudine/Zidovudine: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Lopinavir/Ritonavir: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
        </group>
        <group group_id="B3">
          <title>NVP Arm</title>
          <description>Participants in Arm 2 will have CD4 counts less than 200 cells/mm3 and will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
Nevirapine: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="285"/>
            <count group_id="B2" value="275"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="730"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="730"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="730"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="730"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Botswana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Virologic Suppression</title>
        <description>Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter</description>
        <time_frame>Throughout study, including breastfeeding, assessed up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TZV Arm</title>
            <description>Participants in Arm 1A will have CD4 counts of 200 cells/mm3 or more and will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Trizivir: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Kaletra Arm</title>
            <description>Participants in Arm 1B will have CD4 counts of 200 cells/mm3 or more and will receive LPV/RTV and 3TC/ZDV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Lamivudine/Zidovudine: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Lopinavir/Ritonavir: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP Arm</title>
            <description>Participants in Arm 2 will have CD4 counts less than 200 cells/mm3 and will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
Nevirapine: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virologic Suppression</title>
          <description>Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="256"/>
                    <measurement group_id="O3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of HIV+ Infants</title>
        <description>Number of infants with HIV-positive status</description>
        <time_frame>Throughout study, including breastfeeding, assessed up to 24 months</time_frame>
        <population>Analysis is based on actual number of available patients, and may not perfectly match the Patient Flow module.</population>
        <group_list>
          <group group_id="O1">
            <title>TZV Arm</title>
            <description>Participants in Arm 1A will have CD4 counts of 200 cells/mm3 or more and will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Trizivir: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Kaletra Arm</title>
            <description>Participants in Arm 1B will have CD4 counts of 200 cells/mm3 or more and will receive LPV/RTV and 3TC/ZDV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Lamivudine/Zidovudine: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Lopinavir/Ritonavir: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP Arm</title>
            <description>Participants in Arm 2 will have CD4 counts less than 200 cells/mm3 and will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
Nevirapine: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HIV+ Infants</title>
          <description>Number of infants with HIV-positive status</description>
          <population>Analysis is based on actual number of available patients, and may not perfectly match the Patient Flow module.</population>
          <units>Infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TZV Arm</title>
          <description>Participants in Arm 1A will have CD4 counts of 200 cells/mm3 or more and will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Trizivir: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily</description>
        </group>
        <group group_id="E2">
          <title>Kaletra Arm</title>
          <description>Participants in Arm 1B will have CD4 counts of 200 cells/mm3 or more and will receive LPV/RTV and 3TC/ZDV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
Lamivudine/Zidovudine: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Lopinavir/Ritonavir: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily</description>
        </group>
        <group group_id="E3">
          <title>NVP Arm</title>
          <description>Participants in Arm 2 will have CD4 counts less than 200 cells/mm3 and will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
Nevirapine: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 or 4 Laboratory Event</sub_title>
                <description>Neutropenia or anemia or liver function test (LFT) abnormality</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roger Shapiro</name_or_title>
      <organization>Harvard TH Chan School of Public Health</organization>
      <phone>617-432-2334</phone>
      <email>rshapiro@hsph.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

